Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer: TEXT and SOFT Trials
Meredith M. Regan(Dana-Farber Cancer Institute), Richard D. Gelber(Harvard University), Barbara Walley, Gini F. Fleming(University of Chicago Medical Center), Carlo Tondini(Ospedale Papa Giovanni XXIII), Henry Gómez(National Cancer Center), Marco Colleoni(European Institute of Oncology), Olivia Pagani(Swiss Group For Clinical Cancer Research), Alan S. Coates(International Breast Cancer Study Group), Giuseppe Viale(University of Milan), Karen N. Price(International Breast Cancer Study Group), Graziella Pinotti(Medica (Italy)), István Láng(Roche (Switzerland)), Aron Goldhirsch(Istituti di Ricovero e Cura a Carattere Scientifico), Prudence A. Francis(Peter MacCallum Cancer Centre)
Cited by 184
Related Papers
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment
|New England Journal of Medicine|1994|3.7k
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
|Annals of Oncology|2013|3.7k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k